SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22%

      Dr. John Cush RheumNow

      2 months ago
      SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX
      Risk of Parkinsons? RA patients have 28% lower Parkinson's risk vs general population (HR 0.72); axSpA had HIGHER risk (

      Dr. John Cush RheumNow

      2 months ago
      Risk of Parkinsons? RA patients have 28% lower Parkinson's risk vs general population (HR 0.72); axSpA had HIGHER risk (HR 1.29). Non-TNF biologics in RA reduced PD risk further (HR 0.74). No effect seen in PsA/axSpA. #EULAR2026 Abstr #POS1116 https://t.co/1vZoZGEu5Z
      What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission?

      Data from 194 patients fro

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission? Data from 194 patients from the SELECT-AXIS2 RCT: ▶️ Remission maintained in 1/4 at48 weeks POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux
      #EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE ris

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 months ago
      #EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk: -VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile) -No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD
      https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t

      Janet Pope Janetbirdope

      2 months ago
      https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t
      #SLE Rx options
      Determining #MOA
      #TYK2 #sig w #deucravacitinib
      #IFN sig in active #SLE
      ⬇️ in
      #anifrolumab
      #upa
      #deu

      Janet Pope Janetbirdope

      2 months ago
      #SLE Rx options Determining #MOA #TYK2 #sig w #deucravacitinib #IFN sig in active #SLE ⬇️ in #anifrolumab #upa #deucra #repeat renal #bx in #obinutuzimab ➡️ Clears B cells #Dapriluzimab & other MOAs ⬇️AntiDNA ⬆️complements #EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336
      #EULAR2026 LB0005 More promising news in #PMR. Phase 3 RCT of Baricitinib + GC Taper in N=46:

      Part 1: BARI vs PBO 65%

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 months ago
      #EULAR2026 LB0005 More promising news in #PMR. Phase 3 RCT of Baricitinib + GC Taper in N=46: Part 1: BARI vs PBO 65% vs 17% GC-Free Remission at WK16 2: PBO-BARI improved response 17% to 65% at WK28 3: Lower remission rate in those stopped BARI vs continued at WK44 @RheumNow https://t.co/D77aHcACJE
      Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials.

      Identifyi

      sheila RHEUMarampa

      2 months ago
      Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials. Identifying high-risk pts and individualizing tx is paramount. LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq
      Abstr LB0009

      Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up.

      VTE

      Antoni Chan MD (Prof) synovialjoints

      2 months ago
      Abstr LB0009 Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up. VTE: HR 1.61 (95% CI 0.97–2.66) non-inferiority not demonstrated MACE: HR 1.06 no cardiovascular excess Serious infections: HR 1.32 (p<0.05) @RheumNow https://t.co/NSNRJi9B4r
      Abstr LB0009

      Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years.

      Safety endpoints

      VTE HR 1.61 non in

      Antoni Chan MD (Prof) synovialjoints

      2 months ago
      Abstr LB0009 Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years. Safety endpoints VTE HR 1.61 non inferiority not met Serious infections HR 1.32 (p<0.05) MACE HR 1.06 reassuring @RheumNow #EULAR2026 https://t.co/nR6TMowlYS
      Top 5 abst in #SjD
      #anifrolumab +RCT
      #ianalumab LTE Rx sustained
      #telitatacept +LTE
      #iana improves u/s parotids
      #TYK2 si

      Janet Pope Janetbirdope

      2 months ago
      Top 5 abst in #SjD #anifrolumab +RCT #ianalumab LTE Rx sustained #telitatacept +LTE #iana improves u/s parotids #TYK2 sig in#SjD OP0002, 0126, 127, 160 POS0284 #EULARbest #EULAR2026 @RheumNow @eular_org
      Aiming for #DORIS #SLE #remission
      Or #LLDAS in #SLE
      Related to ⬆️survival
      #deep outcome in RCTs
      ➡️archived in #

      Janet Pope Janetbirdope

      2 months ago
      Aiming for #DORIS #SLE #remission Or #LLDAS in #SLE Related to ⬆️survival #deep outcome in RCTs ➡️archived in #deucravacitinib ph2 #LTE & ph3 #dapirolizumab & #obintuzimab -achieved in #CAR-T trials in #lupus POS0683, 1364, 0695, OP0338 & several 🚗 T abst #EULAR2026 @RheumNow
      JAK-SPARE: Ph3 RCT on baricitinib for rem induxn in early PMR.
      BARI was effective vs. PBO in inducing & maintaining

      sheila RHEUMarampa

      2 months ago
      JAK-SPARE: Ph3 RCT on baricitinib for rem induxn in early PMR. BARI was effective vs. PBO in inducing & maintaining GC free rem. No new safety signals. New tx option for PMR (esp early). Decreases GC dependence & side effects. LB0005 @RheumNow #EULAR2026 https://t.co/mWrr1RdPCm
      #OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred

      Mrinalini Dey DrMiniDey

      2 months ago
      #OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred oral JAKi over SC TNFi (55% vs 45%) Importantly, own choice led to higher treatment satisfaction, better drug survival & fewer adverse events. @RheumNow #EULARBest https://t.co/iI1n2OGzqY
      Gecacitinib Pan JAK inhibitor in Radiographic axSpA
      2 months ago

      Podcasts

      • PsA Topic Podcast compilation
      • EULAR 2026 Daily Podcast Day 4c
      • EULAR 2026 Daily Podcast Day 4a

      Catch up on Conference Podcasts

      ×